Edition:
United States

Actelion Ltd (ALIOF.PK)

ALIOF.PK on OTC Markets Group

280.00USD
26 Jul 2017
Change (% chg)

$2.00 (+0.72%)
Prev Close
$278.00
Open
$279.00
Day's High
$280.00
Day's Low
$279.00
Volume
4,680
Avg. Vol
736
52-wk High
$286.30
52-wk Low
$138.01

Latest Key Developments (Source: Significant Developments)

Idorsia to start trading on SIX Swiss Exchange as of June 16
Friday, 16 Jun 2017 01:00am EDT 

June 16 (Reuters) - IDORSIA LTD ::‍DISTRIBUTION OF IDORSIA SHARES TO ACTELION SHAREHOLDERS COMPLETES DEMERGER FROM ACTELION​.‍SHARES OF IDORSIA WILL BE LISTED AND TRADING WILL COMMENCE ON SIX SWISS EXCHANGE TODAY, 16 JUNE 2017​.  Full Article

Johnson & Johnson announces completion of acquisition of Actelion
Friday, 16 Jun 2017 01:00am EDT 

June 16 (Reuters) - J&J : :Johnson & Johnson announces completion of acquisition of Actelion.Expects transaction to add about $1.3 billion in sales for 2017 and be accretive to 2017 adjusted earnings per share by approximately $0.07.  Full Article

J&J completes $30 bln takeover of Actelion
Friday, 16 Jun 2017 01:00am EDT 

June 16 (Reuters) - Actelion Ltd :Johnson & Johnson completes acquisition of Actelion.Actelion announces completion of acquisition of Actelion Ltd by Johnson & Johnson for a total purchase price of approximately $30 billion in cash.  Full Article

Johnson & Johnson says expects settlement of Actelion tender offer on June 16, 2017
Friday, 9 Jun 2017 11:30am EDT 

June 9 (Reuters) - Johnson & Johnson : :Johnson & Johnson announces expected settlement of Actelion tender offer on June 16, 2017.Announces receipt of all regulatory approvals required to complete acquisition of Actelion.A Johnson & Johnson subsidiary will initially hold 9.9 percent of shares of Idorsia Ltd.  Full Article

Minerva announces amended agreement for MIN-202 in insomnia
Wednesday, 31 May 2017 04:05pm EDT 

May 31 (Reuters) - Minerva Neurosciences Inc :Minerva announces amended agreement for MIN-202 in insomnia.Janssen cash payments to Minerva of up to $70 million, including $30 million upfront.Minerva phase 2 development payments totaling $13 million to be waived.All shares in co held by an affiliate of Janssen to be repurchased at par value.‍under amended agreement, Minerva will gain global strategic control of development of MIN-202 to treat insomnia​.‍Will retain its current rights to MIN-202 as adjunctive therapy for major depressive disorder​.Amendment and stock repurchase are conditional upon closing of pending acquisition of Actelion .  Full Article

J&J appoints Jane Griffiths to head Actelion unit
Monday, 15 May 2017 12:07pm EDT 

May 15 (Reuters) - Actelion Ltd :Says Johnson & Johnson has appointed Jane Griffiths as global head of Actelion, to take effect upon closing of transaction.Says Otto Schwarz will retire from his position as chief operating officer upon close of transaction.  Full Article

Actelion says J&J deal on track to close towards end of Q2
Thursday, 27 Apr 2017 01:07am EDT 

April 27 (Reuters) - Actelion Ltd :Publication of the definitive notice of the end result of actelion tender offer.Says publication of definitive notice of end result of actelion tender offer.Says transaction remains on track to close towards end of q2 of 2017.  Full Article

Actelion says drug discovery business to be called Idorsia
Wednesday, 15 Mar 2017 02:40am EDT 

Actelion Ltd :Says drug discovery and early clinical pipeline business will be separated into a newly-created entity called idorsia ltd -- agm invitation.  Full Article

Actelion says granted marketing authorization by European Commission for Ledaga
Tuesday, 7 Mar 2017 01:00am EST 

Actelion Ltd :Actelion is granted marketing authorization by the European Commission for Ledaga (chlormethine gel) for the treatment of MF-CTCL.  Full Article

Swiss Takeover Commission OKs J&J offer for Actelion
Thursday, 16 Feb 2017 03:01am EST 

Actelion Ltd :Swiss Takeover Commission says J&J offer for Actelion meets legal requirements.  Full Article

Photo

J&J sees sales growth in near-term; raises 2017 profit forecast

Johnson & Johnson said it expects sales growth to pick up in the second half of the year on strong demand for newer, pricey treatments such as cancer drugs Darzalex and Imbruvica.